Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

Treatment of non-motor symptoms of PD: MDS recommendations

The Movement Disorder Society has presented new recommendations on the treatment of non-motor symptoms of Parkinson’s disease (Seppi et al. Mov Disord 2011;26:S42-S80). The evidence-based review updates recommendations published in 2002 and 2004 (Goetz et al. Mov Disord 2002;17[suppl 4]:S1-S166; Goetz et al. Mov Disord 2005;20:523-539). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address tha…

Treatment of motor symptoms of PD: MDS recommendations

The Movement Disorder Society has presented new recommendations on the treatment of motor symptoms of Parkinson’s disease (Fox et al. Mov Disord 2011;26:S2-S41). The evidence-based review updates recommendations published in 2002 and 2004 (Goetz et al. Mov Disord 2002;17[suppl 4]:S1-S166; Goetz et al. Mov Disord 2005;20:523-539). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you r…

Inhaled ergotamine for migraine: phase III results

…MAP0004, a novel inhaled dihydroergotamine, is effective in the acute management of migraine, according to the results of the phase III FREEDOM-301 study (Aurora et al. Headache 2011; 51:507-517). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

What is a relevant change in ADAS-cog?

…A 3-point change in the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-cog) score appears to be the minimal clinically relevant change for patients with mild Alzheimer’s disease (Schrag et al. J Neurol Neurosurg Psychiatry 2012;83:171-173). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

Oral anti-alpha4-integrin in development

…Firategrast, an oral formulation of a natalizumab-like small molecule, produces a significant reduction in MRI lesions, according to the results of a phase II study (Miller et al. Lancet Neurol 2012; epublished January 5, 2012). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…